Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nuvation Bio (NUVB) Change in Account Payables (2023 - 2025)

Nuvation Bio (NUVB) has disclosed Change in Account Payables for 3 consecutive years, with -$5.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Account Payables rose 2.5% to -$5.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $3.1 million, a 289.3% increase, with the full-year FY2025 number at $3.1 million, up 289.3% from a year prior.
  • Change in Account Payables was -$5.9 million for Q4 2025 at Nuvation Bio, up from -$7.1 million in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $11.9 million in Q2 2025 to a low of -$7.1 million in Q3 2025.
  • A 3-year average of $128916.7 and a median of -$184000.0 in 2023 define the central range for Change in Account Payables.
  • Biggest YoY gain for Change in Account Payables was 3614.22% in 2024; the steepest drop was 3578.05% in 2024.
  • Nuvation Bio's Change in Account Payables stood at -$164000.0 in 2023, then tumbled by 3578.05% to -$6.0 million in 2024, then increased by 2.5% to -$5.9 million in 2025.
  • Per Business Quant, the three most recent readings for NUVB's Change in Account Payables are -$5.9 million (Q4 2025), -$7.1 million (Q3 2025), and $11.9 million (Q2 2025).